•
Dec 31, 2022
Amylyx Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Key Takeaways
Amylyx Pharmaceuticals reported Q4 2022 financial results, featuring net product revenue of $21.9 million and a net loss of $42.7 million, or $0.65 per share. The company's commercial launches of RELYVRIO in the U.S. and ALBRIOZA in Canada are progressing, and they appointed Karen Firestone to the Board of Directors.
Net product revenue for Q4 2022 was $21.9 million.
Cost of sales for Q4 2022 were $2.8 million.
Net loss for Q4 2022 was $42.7 million, or $0.65 per share.
Karen Firestone was appointed to the Company's Board of Directors.
Amylyx
Amylyx
Amylyx Revenue by Segment
Forward Guidance
The company anticipates an opinion from CHMP mid-year and a decision in the third quarter of 2023 at the earliest regarding the Marketing Authorisation Application (MAA) for AMX0035.